Trial Profile
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 28 Feb 2022 Primary endpoint has been met. (Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up), as per Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 07 Oct 2020 Status changed from completed to discontinued.